Does TRICARE Cover Testosterone Cypionate?

TRICARE Formulary Status for Testosterone Cypionate

Testosterone cypionate is listed on the TRICARE Uniform Formulary as a covered generic injectable for the treatment of male hypogonadism. The Department of Defense Pharmacy and Therapeutics Committee reviews formulary placement annually, and generic testosterone cypionate has maintained its position as a preferred agent for several years. The Uniform Formulary designates drugs into tiers that determine copay levels across TRICARE Prime, TRICARE Select, and TRICARE For Life 1.

At military treatment facility (MTF) pharmacies, formulary generics carry a $0 copay. Through TRICARE home delivery (Express Scripts), beneficiaries pay $14 for a 90-day supply of a generic medication. Retail network pharmacies charge $14 for a 30-day generic fill. These copay amounts apply to the 2026 benefit year and are updated by the Defense Health Agency each October 2. Compared to the drug's average cash-pay price of roughly $60/month, TRICARE pricing represents a significant cost advantage for eligible beneficiaries. Non-formulary testosterone products (certain branded gels, pellets, or nasal formulations) carry higher copays or may require a non-formulary override.

Prior Authorization Requirements

TRICARE imposes prior authorization (PA) on testosterone cypionate prescriptions filled outside military pharmacies in most circumstances. The PA process is managed by Express Scripts, TRICARE's pharmacy benefit contractor. Approval criteria center on a confirmed diagnosis of male hypogonadism supported by laboratory evidence 3.

The Endocrine Society's 2018 clinical practice guideline recommends diagnosing hypogonadism only after obtaining at least two morning serum total testosterone measurements below 300 ng/dL, drawn between 7:00 and 10:00 AM using a reliable assay 4. TRICARE's PA criteria closely mirror this guideline. Prescribers must document:

• Two fasting morning total testosterone levels <300 ng/dL on separate days
• Signs or symptoms consistent with testosterone deficiency (fatigue, decreased libido, reduced muscle mass, depressed mood)
• Exclusion of reversible causes such as opioid use, hyperprolactinemia, or uncontrolled obesity
• No active contraindications including untreated polycythemia, severe sleep apnea, or active prostate or breast cancer 5

The American Urological Association's 2018 guideline uses a threshold of 300 ng/dL for total testosterone and agrees that confirmatory testing on a separate morning is required before initiating therapy 6. TRICARE reviewers evaluate submissions against both AUA and Endocrine Society standards. PA difficulty is rated moderate: straightforward cases with clear lab documentation are generally approved within 3 to 5 business days.

Step Therapy: Is It Required?

TRICARE does not impose a formal step-therapy protocol requiring trial and failure of topical testosterone gels before approving injectable testosterone cypionate. This is a common misconception. The Uniform Formulary lists both topical and injectable formulations, and prescribers may select the route based on clinical judgment 7.

Some military treatment facilities may prefer starting with topical formulations due to pharmacy stocking practices. This is a local formulary management decision, not a TRICARE-wide step therapy mandate. If a provider believes intramuscular testosterone cypionate is the appropriate first-line choice, they can prescribe it directly and submit the PA with clinical rationale. The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, used transdermal testosterone gel and demonstrated improvements in sexual function, physical activity, and bone mineral density 8. Both injectable and topical routes are considered acceptable first-line options by major guidelines 9.

Clinically, intramuscular testosterone cypionate offers advantages for patients who prefer biweekly or weekly dosing over daily gel application, who have skin conditions limiting transdermal absorption, or who live with household members at risk for secondary transfer (children, pregnant partners) 10. These clinical reasons are accepted by TRICARE PA reviewers.

How to Submit a Prior Authorization

The PA submission process for TRICARE involves the prescribing provider, not the patient. Providers submit requests electronically through the Express Scripts CoverMyMeds portal or by fax. Required documentation includes:

1. The ICD-10 diagnosis code (E29.1 for testicular hypofunction)
2. Two morning serum total testosterone values with dates and reference ranges
3. Relevant symptom documentation from the clinical encounter
4. Confirmation that contraindications have been screened, including a recent PSA level and hematocrit 11

A 2020 analysis of testosterone prescribing patterns found that prior authorization programs reduced inappropriate testosterone use by approximately 28% without restricting access for men meeting diagnostic criteria 12. TRICARE's PA structure aims for this same balance. Turnaround is typically 72 hours for standard requests. Urgent requests (where the patient has no remaining medication) can be expedited to 24 hours.

If documentation is incomplete, the contractor sends a request for additional information. Providers have 10 business days to respond before the request is closed. Incomplete submissions are the most common reason for initial delays, not clinical denials.

Appealing a TRICARE Denial

Denials happen. A 2019 survey of military health system prescribers reported that roughly 15% of initial testosterone PA requests were denied, most frequently for insufficient laboratory documentation rather than clinical ineligibility 13.

The TRICARE appeal process follows a structured pathway:

First-level reconsideration. The beneficiary or provider contacts Express Scripts within 60 days of denial. New lab values or clinical documentation can be submitted. Express Scripts re-reviews with a pharmacist and physician reviewer. Most overturned denials are resolved at this stage.

Second-level appeal. If reconsideration fails, the beneficiary files a formal appeal with the TRICARE regional contractor (Humana Military for the East Region, Health Net Federal Services for the West Region). This appeal is reviewed by a physician who was not involved in the initial decision.

Third-level appeal. If the regional contractor upholds the denial, the beneficiary can escalate to the Defense Health Agency's Office of the Chief Medical Officer. This level is rarely needed for testosterone cypionate cases.

Key tips for successful appeals: include updated morning testosterone levels if the initial labs were borderline, submit a letter of medical necessity from the prescribing provider, reference the Endocrine Society guideline diagnostic threshold of 300 ng/dL 14, and document symptom burden using a validated instrument such as the Aging Males' Symptoms (AMS) scale. Dr. Shalender Bhasin, principal investigator of the T-Trials, has stated: "Testosterone treatment should be offered to men with unequivocally low testosterone levels and symptoms consistent with androgen deficiency, after a shared decision-making discussion about risks and benefits" 15.

Coverage for Off-Label Uses

TRICARE covers testosterone cypionate specifically for its FDA-approved indication: hypogonadism in males due to conditions that are congenital (Klinefelter syndrome, cryptorchidism) or acquired (testicular injury, chemotherapy, pituitary disorders) 16. Coverage for weight loss is not available under the testosterone cypionate PA pathway. While testosterone replacement in hypogonadal men has been associated with modest reductions in fat mass, a meta-analysis of 59 randomized controlled trials (N = 5,331) found a mean fat loss of only 1.6 kg 17. This effect size does not meet TRICARE's threshold for weight-management pharmacotherapy coverage.

TRICARE does cover FDA-approved weight loss medications (semaglutide 2.4 mg, tirzepatide) through a separate PA pathway with documented obesity-medicine criteria. These are distinct coverage tracks. Prescribing testosterone cypionate with a primary diagnosis of obesity will result in denial.

For female-to-male transgender patients, TRICARE began covering gender-affirming hormone therapy, including testosterone cypionate, in 2016 following a policy change by the Department of Defense. Coverage requires documentation from a behavioral health provider and an endocrinologist or primary care physician with experience in transgender medicine 18.

Monitoring Requirements Under TRICARE

Once approved, ongoing TRICARE coverage for testosterone cypionate requires periodic monitoring consistent with Endocrine Society and AUA guidelines. The standard monitoring schedule includes:

• Hematocrit: checked at baseline, 3 to 6 months after initiation, then annually. The FDA label warns against use in men with hematocrit above 55% due to increased thrombotic risk 19. A 2022 retrospective cohort study (N = 15,401) found that testosterone therapy was associated with a hematocrit rise of 3 to 5 percentage points on average 20.
• PSA: measured at baseline, 3 to 6 months, then annually for men over 40. The Endocrine Society recommends urological evaluation if PSA rises above 4.0 ng/mL or increases by more than 1.4 ng/mL within 12 months 21.
• Serum testosterone trough levels: drawn just before the next injection to confirm adequacy. Target trough is 400 to 700 ng/dL for most men.
• Lipid panel and metabolic markers: assessed at baseline and annually, given that testosterone therapy can reduce HDL cholesterol by 5 to 10% 22.

TRICARE PA renewals typically occur every 12 months. Renewal requires documentation that monitoring labs are current, hematocrit remains below 54%, and symptoms have responded to therapy. The TRAVERSE trial (N = 5,246), published in the New England Journal of Medicine in 2023, provided reassurance that testosterone replacement in men aged 45 to 80 with hypogonadism and cardiovascular risk factors did not significantly increase the incidence of major adverse cardiovascular events compared to placebo (hazard ratio 0.96 to 95% CI 0.78 to 1.17) 23.

Cost Comparison: TRICARE vs. Cash Pay

For most military beneficiaries, TRICARE pricing makes testosterone cypionate one of the most affordable prescription medications available. A direct comparison:

| Channel | Cost per month | |---|---| | MTF pharmacy | $0 | | TRICARE home delivery (90-day) | ~$4.67/month ($14 per fill) | | TRICARE retail network | $14/month | | Cash pay (no insurance) | ~$60/month | | Manufacturer list price | ~$100/month |

Active-duty service members enrolled in TRICARE Prime pay $0 at MTF pharmacies and $0 copay through home delivery for generic formulary drugs. Retirees and dependents on TRICARE Select face the copay structure above. TRICARE For Life beneficiaries (Medicare-eligible retirees) typically pay the Medicare Part D copay, which may differ from TRICARE Select rates.

One important distinction: manufacturer savings cards and copay assistance programs cannot be applied to TRICARE prescriptions. Federal law prohibits the use of manufacturer coupons with government-funded insurance programs, including TRICARE, Medicare, and Medicaid. The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) governs this restriction 24. Beneficiaries who see manufacturer copay card offers should be aware these apply only to commercial insurance plans.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's testosterone therapy guidelines, has noted: "Generic testosterone cypionate remains the most cost-effective formulation for testosterone replacement, and insurance coverage for this indication is generally strong when diagnostic criteria are met" 25.

Choosing the Right TRICARE Pharmacy Channel

Beneficiaries filling testosterone cypionate have three pharmacy options under TRICARE, and the choice affects both cost and convenience:

MTF pharmacy offers the lowest cost ($0) but requires an in-person visit to a military treatment facility. Not all MTFs stock testosterone cypionate for outpatient dispensing, and availability may vary. Active-duty members stationed on base often find this the most practical option.

TRICARE home delivery through Express Scripts provides 90-day supplies mailed to the beneficiary's address. This is the best option for retirees and dependents who want predictable refills. Prescriptions can be transferred by calling Express Scripts or through the online portal.

Retail network pharmacies (CVS, Walgreens, Walmart, and others in the Express Scripts network) offer same-day fills at a higher per-fill copay. This option works well for initial prescriptions or when a patient needs medication before a home delivery shipment arrives.

Standard testosterone cypionate dosing ranges from 50 to 200 mg intramuscularly every 1 to 2 weeks 26. A single 10 mL vial of 200 mg/mL concentration contains enough medication for multiple injections, making each fill last several weeks to months depending on the prescribed dose.